# US 2026/0083718 A1 · Piperidine urea derivatives for obesity therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083718 A1
- Document ID: US20260083718A1
- Status: Published application
- Kind: A1
- Application number: 19/338,129
- Filed: 2025-09-24
- Published: 2026-03-26
- Earliest claimed: 2024-09-24
- Assignees: Astrizi Bio, Inc.
- Applicants: Astrizi Bio, Inc.
- Inventors: Ish Khanna; Sivaram Pillarisetti; Hans Marcus Malkmus; Kathrin Christin Kortschak
- Web page: https://patentgrep.com/patent/US20260083718A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject matter disclosed herein is generally directed to methods and compositions for preventing, suppressing or treating obesity and/or obesity-induced disorders, specifically, select piperidine urea-derived compounds as a monotherapy or a combination therapy with glucagon-like peptide 1 (GLP-1—SEQ ID NO: 1) receptor agonist and/or dual GLP-1 (SEQ ID NO: 1) and glucose-dependent insulinotropic polypeptide GIP (SEQ ID NO: 8) receptor agonist for the treatment of obesity.

## Claims

### Claim 1

A method of treating obesity and/or obesity-induced disorder(s) comprising:
administrating to a subject a therapeutic amount of at least one compound of Formula I:
where
R1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R1 is aryl, heteroaryl or heterocycloalkyl, R1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO2NHR2, or COR3;
R2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;
R3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;
R4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO2R5, or COR3;
R5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;
R6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl;
X is selected from O, (CH2)p, NH and p is from 0-2;
Y1-Y2 are selected from CH—CH2, CH—O, or C═CH, however when Y1-Y2 is CH—O, X is selected from O or NH or R1 is not hydrogen; and
Y3 is selected from H or Me,
its stereoisomers or pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein Y3 is H, Y1-Y2 is C═CH, and the compound is a compound according to Formula III
where
R1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R1 is aryl, heteroaryl or heterocycloalkyl, R1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO2R5, SO2NHR2, or COR3;
R2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;
R3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;
R4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO2R5, SO2NHR2, COR3;
R5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;
R6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl; and
X is selected from O, (CH2)p, NH and p is from 0-2,
its stereoisomers or pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein Y3 is H, Y1-Y2 is CH—CH2, wherein X is selected from O, (CH2)p, NH; wherein p is selected from 0-2, however when p=0, R1 is not aryl, and the compound is a compound according to Formula IV
where
R1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R1 is aryl, heteroaryl or heterocycloalkyl, R1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO2R5, SO2NHR2, COR3;
R2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;
R3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;
R4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO2R5, COR3;
R5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;
R6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl. Aryl or heteroaryl may optionally be substituted one or more times with groups or substituents such as alkyl, hydroxy, halogen, haloalkyl; and
X is selected from O, (CH2)p, NH; wherein p is selected from 0-2,
its stereoisomers or pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of Formula 1 is one or more of the following compounds
its stereoisomers or pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound of Formula 1 is one or more of the following compounds:
its stereoisomers or pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein the compound inhibits SEQ ID NO: 2 at a concentration (IC50) of less than 100 nM and has at least a 10-fold selectivity over inhibition (IC50) of SEQ ID NO: 10.

### Claim 7 (depends on 1)

The method of claim 1 wherein to treat obesity the compound is administered to induce weight loss and/or inhibit weight gain.

### Claim 8 (depends on 1)

The method of claim 1, wherein the obesity induced disorder is at least one of a metabolic syndrome, insulin resistance, glucose intolerance, abnormal lipid levels, fatty liver, hepatic steatosis, non-alcoholic fatty liver disease, renal dysfunction, leptin resistance, cancer, increased fat mass, reduced lean muscle mass, increased inflammation, and/or cardiovascular disease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the obesity related disorder is at least one of impaired glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, and/or metabolic syndrome.

### Claim 10 (depends on 8)

The method of claim 8, wherein abnormal lipid levels are characterized by one or more of the high levels of triglyceride, low density lipoprotein (LDL) and/or cholesterol

### Claim 11 (depends on 8)

The method of claim 8, which results in reduction in levels of at least one inflammatory marker selected from SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 12, and/or SEQ ID NO: 6.

### Claim 12 (depends on 8)

The method of claim 8 which results in reduction in levels of at least one marker related to cardiovascular disease: C-reactive protein (CRP), lipoprotein(a) [Lp(a)].

### Claim 13 (depends on 8)

The method of claim 8 which results in improvement in leptin sensitivity.

### Claim 14 (depends on 8)

The method of claim 8 which results in reduced fat mass.

### Claim 15 (depends on 8)

The method of claim 8 which results in reduced fat mass while preserving lean muscle mass.

### Claim 16 (depends on 8)

The method of claim 8 which results in increased lean muscle mass.

### Claim 17 (depends on 8)

The method of claim 8 which prevents or treats liver steatosis or non-alcoholic fatty liver disease.

### Claim 18 (depends on 1)

The method as claimed in claim 1, wherein the compound is administered at a dose of substantially 10 mg/day to substantially 1000 mg/day.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administrating at least one further compound selected from at least one SEQ ID NO: 1 receptor agonist, at least one glucose-dependent insulinotropic polypeptide receptor agonist, at least one dual SEQ ID NO: 1 and SEQ ID NO: 8 receptor agonist, at least one SEQ ID NO: 9 inflammasome inhibitor, amylin agonist, glucagon agonist, SEQ ID NO: 15 agonist, SEQ ID NO: 16 agonist, SEQ ID NO: 13 receptor agonist, SEQ ID NO: 14 inhibitor, myostatin inhibitor, orlistat, phentermine/topiramate, naltrexone/bupropion, or a combinations of the above.

### Claim 20 (depends on 19)

A method of claim 19 wherein at least one SEQ ID NO: 1 receptor agonist is selected from a group consisting of: liraglutide and semaglutide.

### Claim 21 (depends on 19)

A method of claim 19 wherein the dual SEQ ID NO: 1 and SEQ ID NO: 8 receptor agonist is selected from tirzepatide.

### Claim 22

A method of treating obesity comprising administering to a subject a therapeutic amount of a SEQ ID NO: 2 inhibitor along with therapeutic amount of at least one further compound which is selected from at least one SEQ ID NO: 1 receptor agonist, at least one glucose-dependent insulinotropic polypeptide receptor agonist or at least one dual SEQ ID NO: 1 and SEQ ID NO: 8 receptor agonist.

### Claim 23

A method of preventing or treating obesity and obesity-induced disorders such as insulin resistance and metabolic syndrome, the method comprising administering to a subject a therapeutic amount of a SEQ ID NO: 2 inhibitor along with therapeutic amount of at least one further compound which is selected from at least one SEQ ID NO: 1 receptor agonist, at least one glucose-dependent insulinotropic polypeptide receptor agonist or at least one dual SEQ ID NO: 1 and SEQ ID NO: 8 receptor agonist.
